Screener / SEC EDGAR /CIK 0001516513 /10-K filed May 19, 2026, compared with May 20, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Technology · IT Services

Doximity, Inc. DOCS

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of DOCS's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Feb 23, 2026
Questions asked 24 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 3 UPLOAD
  2. 2. Questions in them 24 numbered comments
  3. 3. Company replies 2 CORRESP
  4. 4. Reviews closed 1 of 2 closing letter

Half the closed reviews took 31 days or less from the first letter to the closing letter.

Form 10-K for the Year Ended March 31, 2025

2026-02-23 to 2026-03-26 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2026-03-26
RevenueResults discussion (MD&A)Liquidity and cash
After reviewing your response to this letter, we may have additional comments. Business, page 3
SEC asked
You disclose you had more than 620,000 unique active providers use your clinical workflow tools in the quarter ended March 31, 2025. To enhance comparability for investors, please show us how you intend to revise to define "use" of your clinical workflow tools (for example, clarify the types of activities and useage duration needed for this metric). Please also provide comparable metrics for all periods presented.
Rest of the question

Management's Discussion and Analysis of Financial Condition and Results of Operations Key Business and Financial Metrics, page 46 In your earnings calls for the year ended March 31, 2025 and the six months ended September 30, 2025, you make reference to a number of user engagement metrics that are not described or defined in your MD&A. Among the metrics discussed in those earnings calls were: • Number of quarterly, monthly, weekly and daily active users 2. • Number of unique newsfeed users • Number of newsfeed articles read or tapped • Number of unique active prescribers using workflow tools • Adoption of AI-driven features Since user engagement metrics appear to be an important factor management considers in evaluating the business and allocating resources, please show us how you intend to revise to define, quantify and analyze these metrics as part of your MD&A. Refer to SEC Release 33-10751. 3. You disclose that (as of March 31, 2025) your platform has over two million registered members, including more than 80% of U.S. physicians. We note from your disclosures on page 4 that your platform provides most medical professions with a pre-populated professional profile based on publicly and commercially available third-party data. Please show us how you intend to revise to clarify if the 80% figure includes only actively practicing physicians who have completed your identity and credential verification process or if some other criteria were used. Please also show us how you intend to revise to clarify how the number of registered members compares to the number of quarterly, monthly, weekly and daily active users of your platform. Comparison of the Fiscal Years Ended , page 50 4. You indicate that average revenue per existing Marketing Solutions customer increased by 22% during fiscal 2025. In your May 15, 2025 earnings call, your CEO indicated that newsfeed was both your most widely used and most monetized product. Please show us how you intend to revise to provide greater insight to investors about your revenue trends over time by disclosing disaggregated revenues by modules (Newsfeed, Workflow, and Peer) for each period presented. It appears you have this information readily available and that management is actively using it to evaluate your business. Refer to Item 303(b)(2) of Regulation S-K. Comparison of the three and nine months ended December 31, 2025 and 2024, page 33 5. In your February 5, 2026 earnings call, management spent time discussing some "shortterm industry-wide policy headwinds" that are impacting client budgets and advertising booking rates for pharmaceutical companies. Management also indicated that higher AI infrastructure investment has impacted the results through the period ended December 31, 2025 and is expected to continue impacting future periods. Please show us how you intend to revise to address (and quantify where possible) any known material trends, demands, commitments, events or uncertainties that are reasonably likely to result in a material change to your liquidity or results from operations. Please refer to Item 303(c) of Regulation S-K.

DOCS answered
The Company respectfully acknowledges the Staff’s comment and confirms that beginning with its Annual Report on Form 10-K for the fiscal year ending March 31, 2026 (the “2026 10-K”) it will provide (i) additional disclosure defining the use of its clinical workflow tools by unique active providers on a quarterly basis and (ii) comparable data on the metric for the prior period.

The following is an example of how the Company expects to provide this additional disclosure, which will be included in the Key Business and Financial Metrics section of Management’s Discussion and Analysis of
Rest of the answer

Financial Condition and Results of Operations beginning with the 2026 10-K.

“Quarterly Unique Active Providers using Workflow Tools. Quarterly unique active providers1 using our Workflow Tools is a key performance indicator of our platform’s adoption and long-term growth potential among providers on our platform. We calculate the number of unique active providers by counting providers who securely login and use any of the following workflow functions on our technology platform during the quarter: placing phone calls or video calls lasting more than 10 seconds, sending voicemails, or sending secure text messages using our Dialer communications tools; sending or receiving faxes; submitting a prompt on Doximity GPT, our HIPAA‑compliant generative AI clinical research tool and writing assistant; conducting research on prescription drugs; reviewing AI responses for our PeerCheck feature; scheduling via our on-call scheduling tool, Amion; or using our HIPAA-compliant ambient note taking tool, Scribe, for a patient visit. Each provider is counted once per quarter, even if they use multiple tools or use them many times.”

March 31,

2026 2025

Quarterly unique active providers using our workflow tools [●] 634,000

If, in the future, the Company adds new functions to its technology platform, it will assess whether those functions affect its methodology for calculating unique active providers and update its disclosures as appropriate.

Read in the reply
In its next report

First report after the company's reply of Mar 23, 2026: 10-K filed May 19, 2026 ↗, against the 10-K filed May 20, 2025 ↗.

The part of the filing the question names could not be found in both reports. Read them on sec.gov.

Also in this review: closing letter, 2026-03-26

Form S-1

2021-04-01 to 2021-06-04 · 23 questions · 2 letters from the SEC, 1 from the company
No closing letter
RevenueResults discussion (MD&A)ControlsRisk factorsKey metricsNon-GAAP measuresGoodwill and impairmentAcquisitions
Prospectus Summary · Overview, page 1
SEC asked (1)
You describe yourself as the “leading digital platform for U.S. medical professionals.” Please provide the basis for your characterization that you have a leading software platform and describe how this leadership is defined and/or determined. For example, it is not clear whether you are basing this on objective criteria such as market share based on revenues for competing software platforms in your industry.
DOCS answered
On behalf of our client, Doximity, Inc. (“Doximity” or the “Company”), we submit this supplemental letter to assist the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) in its review of the Company’s Registration Statement on Form S-1 (File No. 333-256584, confidentially submitted to the Commission on March 5, 2021, April 16, 2021, and May 7, 2021, and publicly filed on May 28, 2021 (the “Registration Statement”). Because of the commercially sensitive nature of information contained herein, this submission is accompanied by the Company’s request for confidential treatment for selected portions of this letter.
Rest of the letter

The Company has filed a separate letter with the Office of Freedom of Information and Privacy Act Operations in connection with the confidential treatment request, pursuant to Rule 83 of the Commission’s Rules on Information and Requests, 17 C.F.R. § 200.83. For the Staff’s reference, we have enclosed a copy of the Company’s letter to the Office of Freedom of Information and Privacy Act Operations, as well as a copy of this correspondence, marked to show the portions redacted from the version filed via EDGAR and for which the Company is requesting confidential treatment. Prior to the completion of the Company’s initial public offering (the “IPO”), the Company intends to file an amended and restated certification of incorporation which will effect the reclassification of its common stock into Class A common stock and Class B common stock (the “Reclassification”) and a [****]-for-[*****] forward stock split (the “Split”) of the Company’s capital stock. All information presented in this supplemental letter has been adjusted to reflect such Reclassification as if it had already occurred prior to the date hereof. No information presented in this supplemental letter has been adjusted to reflect such Split, and all numbers in this supplemental letter are presented on a pre-Split basis. The Company supplementally advises the Staff that on June 2, 2021, representatives of Morgan Stanley & Co. LLC, Goldman Sachs & Co., LLC, and J.P. Morgan Securities LLC, the lead underwriters for the IPO (the “Lead Underwriters”), on behalf of the underwriters, advised the Company that, based on then-current market conditions, they anticipated that the underwriters would recommend to the Company a preliminary price range of $[****] to $[****] per share (the “Preliminary Price Range”), resulting in a midpoint of the Preliminary Price Range of $[****] per share (the “Midpoint Price”). The Company further advises the Staff that the Preliminary Price Range represents the Company’s belief of what the indicative price range to be disclosed in the preliminary prospectus may be, but that the actual indicative price range to be included in the preliminary prospectus will not be determined until the Company completes a valuation process with the underwriters and will be narrower than the Preliminary Price Range. This valuation process is expected to occur shortly before the printing and filing of the preliminary prospectus for the commencement of the roadshow for the IPO. Therefore, the Preliminary Price Range is subject to further change, which may result from various factors, including then-current market conditions and subsequent business, market, and other developments affecting the Company. The indicative price range to be included in the preliminary prospectus, when determined, will be included in an amendment to the Registration Statement prior to the distribution of any preliminary prospectuses to potential investors. This letter provides a discussion of the Company’s approach to option pricing and fair value determinations with respect to the option grants made by the Company’s board of directors (the “Board”) for the preceding twelve months through the date of this letter. Reference is made to Comment No. 19 in the letter from the Staff dated April 1, 2021 addressed to Anna Bryson, Chief Financial Officer of the Company, with respect to the Company’s Confidential Draft Registration Statement on Form S-1 submitted on March 5, 2021 regarding the fair value assumptions used to determine share-based compensation expense for equity grants made after December 31, 2020. In this response, the Company has included a table with the details and fair value assumptions for grants after December 31, 2020 through the date of this letter and has provided general commentary on the fluctuations in the estimated fair value of its common stock. Equity Award Issuances by the Company in the Preceding Twelve Months Information regarding grants of stock options to the Company’s directors and employees in the preceding twelve months is summarized in the following table: Grant Date Number of Shares Underlying Options Granted Fair Value of Underlying Share of Common Stock *Fair value determined for financial reporting purposes by assuming that the fair value of the Company’s common stock increased on a linear basis from the March 31, 2021 fair value of $25.12 to the midpoint of the Preliminary Price Range to be set forth in the preliminary prospectus filed in connection with the IPO. As described in the section titled “Common Stock Valuation” on page 91 of the Registration Statement, the fair value of the Company’s Class A common stock has historically been determined by the Board. Given the absence of a public trading market for the Company’s Class A common stock, and in accordance with the American Institute of Certified Public Accountants Accounting and Valuation Guide: Valuation of Privately-Held Company Equity Securities Issued as Compensation (the “AICPA Practice Guide”), the Board exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of the Company’s Class A common stock, including contemporaneous third-party valuations of its Class A common stock (each, a “Valuation Report,” and collectively, the “Valuation Reports”). For the March 31, 2020 and June 30, 2020 Valuation Reports, the fair value of the total shareholders’ equity was derived using a weighting of an income approach and a market approach. For the September 30, 2020, December 31, 2020, and March 31, 2021 Valuation Reports, the fair value of the total shareholders’ equity was derived using a weighting of an income approach and a market approach for the Non-IPO scenario. For the IPO scenario, the fair value of the total shareholders’ equity was derived using the discounted value of the estimated pre-money IPO equity value. The income approach uses the Discounted Cash Flow (“DCF”) method, which estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate based on our estimated weighted-average cost of capital. In deriving enterprise value using the market approach, the Company used the Guideline Public Company (“GPC”) method. The GPC method involves a three-step methodology: (i) identifying publicly-traded companies in the same or similar lines of business; (ii) calculating market multiples for such identified companies based on their respective historical financial results and projected growth as of the valuation date; and (iii) applying such market multiples to the Company’s historical financial data and internal financial forecast. After determining enterprise value, the Valuation Reports utilized an option pricing method (“OPM”) to allocate the enterprise value of the Company to the various classes and series of the Company’s capital stock. The March 31, 2020 and June 30, 2020 Valuation Reports employed single scenario option pricing models. The September 30, 2020, December 31, 2020, and March 31, 2021 Valuation Reports each employed a multiple-scenario OPM whereby such reports considered two potential future scenarios (an IPO scenario and a Non-IPO scenario) to allocate the enterprise value of the Company to the various classes and series of the Company’s capital stock. The Company also considered the transaction price of secondary market transactions with third-party investors in the Company’s capital stock in its Valuation Reports. No equity financing rounds by the Company occurred during the preceding twelve months. The results of the March 31, 2020 Valuation Report are summarized in the table below, along with the Company’s assessment of the fair value used for computing stock-based compensation expense. Value per share of Common Stock (prior to DLOM) $3.81 Indicated value per share of Common Stock $2.93 $10.32 Concluded fair market value per share of Common Stock $3.08 The March 31, 2020 Valuation Report applied DCF and GPC methodologies with 70% and 30% weighting, respectively. This valuation report did not include an IPO scenario as the Company had not begun IPO readiness activities until after the valuation date. The Company also carried out secondary sales prior to the valuation date, which involved the sale of 312,027 shares or 0.35% of the diluted equity in the Company, at a weighted-average share price of $10.32 per share. Given the relative insignificance of the secondary transactions, the weighted-average price of the secondary transactions was provided a 2% weight on the equity value at March 31, 2020, and was considered reasonable. The results of the June 30, 2020 Valuation Report are summarized in the table below, along with the Company’s assessment of the fair value used for computing stock-based compensation expense. Value per share of Common Stock (prior to DLOM) $5.63 Indicated value per share of Common Stock $4.22 $7.96 Concluded fair market value per share of Common Stock $4.41 The June 2020 Valuation Report applied GPC and DCF methodologies at equal weighting. This valuation report did not include an IPO scenario as the Company had not begun IPO readiness activities until after the valuation date. The Company also carried out secondary sales prior to the valuation date, which involved the sale of 112,117 shares, or 0.12% of the total diluted equity in the Company, at a weighted-average share price of $7.96 per share. Given the relative insignificance of the secondary transactions, the weighted-average price of the secondary transactions was provided a 5% weight on the equity value at June 30, 2020 and was considered reasonable. The results of the September 30, 2020 Valuation Report are summarized in the table below, along with the Company’s assessment of the fair value used for computing stock-based compensation expense. Value per share of Common Stock (prior to DLOM) $8.66 $14.66 Indicated value per share of Common Stock $6.71 $12.82 $8.06 Concluded fair market value per share of Common Stock $8.23 In September 2020, the Company began preparing for its potential IPO and anticipated completing the same in June of 2021. The Company selected its legal counsel during this time and started planning potential IPO activities although it had not yet engaged underwriters for the potential IPO. The Company started using a multiple-scenario OPM to allocate the enterprise value to the various classes and series of the Company’s capital stock. For the Non-IPO scenario, we continued to assign an equal weighting to the GPC and DCF methods to arrive at the enterprise fair value of the Company. The Company added an IPO scenario wherein the discounted expected pre-money total equity valuation was weighted at 25% probability, before consideration of secondary sales. With respect to the IPO scenario, the September 30, 2020 Valuation Report considered the uncertainties around the pricing and execution of a successful IPO when determining the appropriate weighting for such an outcome. The DLOM was determined to be 12.5% under the IPO scenario, which was in line with the market, company maturity and expected exit timing. The DLOM for the Non-IPO scenario was reduced to 22.5% from 25% in the prior valuation. The secondary sales transactions during the twelve months prior to the valuation date included sales of 439,308 shares, at a weighted-average share price of $8.06 per share, or 0.5% of the total diluted equity in the Company. Given the relative insignificance of the secondary transactions, the weighted-average price of the secondary transactions was provided a 5% weight on the equity value at September 30, 2020 and was considered reasonable. The results of the December 31, 2020 Valuation Report are summarized in the table below, along with the Company’s assessment of the fair value used for computing stock-based compensation expense. Value per share of Common Stock (prior to DLOM) $16.31 $27.13 Indicated value per share of Common Stock $12.64 $23.74 $7.32 Concluded fair market value per share of Common Stock $16.52 The same methods that were utilized to determine fair market value in the September 30, 2020 Valuation Report were used in the December 31, 2020 Valuation Report. During the quarter ended December 31, 2020, the Company had a strong sales quarter resulting in an increase in its revenue forecast. As a result, there was a significant increase in the enterprise fair value of the Company for both the IPO scenario and the Non-IPO scenario. During this period, the Company continued to prepare for a potential IPO, including engaging underwriters in November 2020 and holding various meetings with the underwriters and legal counsel with the expectation that the IPO would be consummated in September 2021. As a result, and as described in the table above, the December 31, 2020 Valuation Report increased the weighting for the IPO scenario to 35% from 25% utilized in the prior valuation report. While the Company had secondary transactions, the volume of transactions represented only 0.22% of the total diluted equity in the Company and these transactions pre-dated the above-described IPO progress. These transactions were provided no weight in the estimation of fair value of common stock since they did not appear to reflect all information available as of the valuation date and were materially below the value of the common stock as estimated by the valuation analysis. The results of the March 31, 2021 Valuation Report are summarized in the table below, along with the Company’s assessment of the fair value used for computing stock-based compensation expense. Value per share of Common Stock (prior to DLOM) $21.62 $30.53 Indicated value per share of Common Stock $17.84 $28.24 $10.73 Concluded fair market value per share of Common Stock $25.12 The Company believes that the following significant factors contributed to the increase in the fair value of its common stock. During the quarter ended March 31, 2021, the Company continued to experience a strong sales quarter resulting in an increase in its revenue forecast. This contributed to an increase in the enterprise fair value of the Company for both the IPO scenario and the Non-IPO scenario. In addition, in March 2021, the probability for the IPO scenario increased from 35% in December 2020 to 70% in March 2021 reflecting the progress made towards the going public milestones such as the confidential Draft Registration Statement on Form S-1 submission with the Commission on March 5, 2021. By the time of the March 31, 2021 Valuation Report, the Company also accelerated its IPO timeline from September 2021 to June 2021 and reduced its DLOM from 12.5% in December 2020 to 7.5% in March 2021 under the IPO scenario, which was in line with the market, company maturity and expected exit timing. The DLOM for the Non-IPO scenario was reduced to from 22.5% in the prior valuation to 17.5%. While the Company had secondary transactions, the volume of transactions represented only 0.25% of the total diluted equity in the Company and these transactions pre-dated the above-described IPO progress. These transactions were provided no weight in the estimation of fair value of common stock since they did not appear to reflect all information available as of the valuation date and were materially below the value of the common stock as estimated by the valuation analysis. Fair Value Used for Computing Stock-based Compensation Expense For financial reporting purposes and as further described below, the Company retrospectively assessed the fair value used for computing stock-based compensation expense after considering the fair value reflected on the relevant Prior Valuation Report and other facts and circumstances on the date of grant, and used linear interpolation to determine the estimated fair value. The Company believes that the linear interpolation methodology provided a reasonable basis for the valuation of the Class A common stock for financial reporting purposes in the instances where the Company did not identify any single event that would have caused a material change in the fair value of the Class A common stock. The Company determined the fair value per share for the June 10, 2020 grants based on the interpolated fair value of the Company’s Class A common stock from March 31, 2020 to June 30, 2020, as set forth in the June 30, 2020 Valuation Report. The Company determined the fair value per share for the September 2, 2020 and September 29, 2020 grants based on the interpolated fair value per share of the Company’s Class A common stock from June 30, 2020 to September 30, 2020, as set forth in the September 30, 2020 Valuation Report. The Company believes that this straight-line methodology provides the most reasonable basis for the valuation of its Class A common stock because it did not identify any single event that occurred from June 30, 2020 through September 29, 2020 that would have caused a material change in fair value. The Company determined the fair value per share for the November 21, 2020 and December 22, 2020 grants based on the interpolated fair value per share of the Company’s Class A common stock from September 30, 2020 to December 31, 2020, as set forth in the December 31, 2020 Valuation Report. The Company believes that this straight-line methodology provides the most reasonable basis for the valuation of its Class A common stock because it did not identify any single event that occurred from September 30, 2020 through the date of the December 22, 2020 grants that would have caused a material change in fair value. The Company determined the fair value per share for the January 28, 2021, February 5, 2021, and February 16, 2021 grants based on the interpolated fair value per share of the Company’s Class A common stock from December 31, 2020 to March 31, 2021, as set forth in the March 31, 2021 Valuation Report. The Company believes that this straight-line methodology provides the most reasonable basis for the valuation of its Class A common stock because it did not identify any single event that occurred from December 31, 2020 through the date of the February 16, 2021 grants that would have caused a material change in fair value. The fair value for the May 7, 2021 and May 26, 2021 grants were determined based on the interpolated fair value per share of the Company’s Class A common stock, as determined by the Board considering the most recently completed March 31, 2021 Valuation Report (which provided that the Company’s fair value per share as of $25.12), and the midpoint of the Roadshow Price Range to be set forth in the preliminary prospectus filed in connection with the IPO. Analysis of Differences Between the Fair Value of the Company’s Class A Common Stock Based on the March 31, 2021 Valuation Report and the Midpoint Price As noted above, the Preliminary Price Range is between $[****] to $[****] per share of Class A common stock. The Preliminary Price Range was determined based, in part, on discussions among the management of the Company, the Board, and the Lead Underwriters. In addition, the Preliminary Price Range was derived using a combination of valuation methodologies that differ from that used by the Board and the Valuation Reports in determining the fair value of the Company’s Class A common stock. The valuation methodologies considered in deriving the Preliminary Price Range included the valuations of publicly-traded companies across a range of metrics, with a primary focus on revenue, EBITDA, and free cash flow. The Company believes the principal factors that contributed to the $[****] per share difference between $[****] per share, the Midpoint Price, and $25.12, the per share fair value of the Company’s Class A common stock based on the March 31, 2021 Valuation Report, were as follows: •The Board made its determination of the fair value of the Company’s Class A common stock as of March 31, 2020, June 30, 2020, September 30, 2020, December 31, 2020, and March 31, 2021 based on the information available as of such dates, taking into account, among other factors, the uncertainty and volatility created by the COVID-19 pandemic, including its impact on economic growth, adoption of digital marketing and telehealth applications, the interest rate environment, market volatility, and global economic trends. As of March 31, 2020, June 30, 2020, September 30, 2020, December 31, 2020, and March 31, 2021, the dates of the relevant Valuation Reports, the impact of the COVID-19 pandemic on the Company, market conditions, and the global economy were nascent and rapidly evolving. The uncertainty caused by the COVID-19 pandemic also impacted the Company’s ability to forecast revenue and profitability for use in the Valuation Reports, and the Company’s profitability forecasts have consistently been exceeded and revised upward with each Valuation Report subsequent to March 31, 2020. •The Preliminary Price Range was informed by recent results of the business. In the quarter ended March 31, 2021, the Company reported revenue of $66.7 million compared to $58.7 million for the quarter ended December 31, 2020 representing growth of 13.6%, and a net income of $21.5 million for the quarter ended March 31, 2021, compared to a net income of $17.2 million for the quarter ended December 31, 2020. [****]. •Based on the Company’s recent financial performance and current market sentiment, the Company expects that there will be significant investor interest in the IPO. The capital markets continue to reward high growth technology companies in expanding addressable markets with exposure to favorable industry trends such as increasing demand for on-line solutions. •Since September 30, 2020, the Company has taken several steps towards the completion of an IPO, including engaging underwriters, holding “testing the waters” meetings, at which the Company received favorable feedback from various potential investors in April 2021, engaged underwriters, and confidentially submitting and publicly filing multiple Registration Statements with the Commission and responding to a number of inquiries by the Commission examiners. •Unlike the valuation methodologies used in connection with the Company’s equity issuances, the Preliminary Price Range does not take into account the probability of alternative outcomes that could yield lower valuations, such as a sale transaction at differing valuations or that the Company may continue as a private, stand-alone entity. Therefore, the Preliminary Price Range effectively weighs a near-term IPO outcome at 100%. In contrast, the September 30, 2020 Valuation Report weighted the probability of a successful IPO within one year of the measurement date at 23.7%, the December 31, 2020 Valuation Report weighted the probability of a successful IPO within one year of the measurement date at 35%, and the March 31, 2021 Valuation Report weighted the probability of a successful IPO within one year of the measurement date at 70%. Given the uncertainty in the capital markets as a result of the COVID-19 pandemic, the probability of consummating a successful IPO was far from certain during these prior periods. •The Preliminary Price Range represents a future price for shares of Class A common stock that, if issued in the IPO, will be immediately freely tradable in a public market, whereas the estimated fair values of the Class A common stock as of June 30, 2020, September 30, 2020, December 31, 2020, and March 31, 2021 appropriately represent contemporaneous estimates of the fair value of shares that were then illiquid and might never become liquid, and as such, were adjusted for a discount due to lack of marketability (“DLOM”). This weighted-average DLOM for the Company’s Class A common stock was 22.5% as of March 30, 2020, 23.8% as of June 30, 2020, 19.0% as of September 30, 2020, 19.0% as of December 31, 2020, and 10.5% as of March 31, 2021. •The holders of the Company’s redeemable convertible preferred stock currently enjoy substantial economic rights and preferences over the holders of its common stock. The Preliminary Price Range assumes the conversion of all of the Company’s redeemable convertible preferred stock upon the completion of its IPO. The corresponding elimination of the preferences and rights enjoyed by the holders of such redeemable convertible preferred stock results in a higher valuation of the Company’s Class A common stock, which is reflected in the Preliminary Price Range. Based on the above analysis, the Company respectfully submits to the Staff that the determination of the fair value of its Class A common stock described above was in accordance with ASC Topic 718 and consistent with the AICPA Practice Guide. Further, the Company believes that the stock-based compensation expense that it recorded through March 31, 2021, is appropriate in light of the foregoing analysis. If you require any additional information on the matters contained in this letter, or if we can provide you with any other information that will facilitate your review, please advise us at your earliest convenience. You may reach me at (650) 752-3227 or [email protected].

One letter for all the questions, without numbered answers. Read the reply
Prospectus Summary · Overview, page 1
SEC asked (2)
Clarify that your revenue generating customers are pharmaceutical and health care system subscribers, not medical professionals.
DOCS answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (3)
We note that you entered into a partnership with U.S. News & World Report. Please revise to provide the material terms of that agreement and file it as an exhibit. Risk Factors If we are unable to implement and maintain effective internal controls over financial reporting...,
DOCS answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (4)
We note your disclosure on page F-9 where you identified and corrected a number of errors subsequent to the issuance of the financial statements for the year ended March 31, 2020. So investors can better understand risks associated with your internal control over financial reporting, please revise to briefly describe the material weaknesses management identified, if any, in your internal controls over financial
Rest of the question

reporting in your (i) financial statement close process, (ii) deferred revenue reconciliation process and (iii) capitalization of internal-use software development costs. For example, explain the reasons for, or the circumstances that resulted in, the weakness in internal controls in these areas, and address the remedial measures taken to address these material weaknesses, if any.

DOCS answered

See the reply above.

Management's Discussion and Analysis of Results of Operations and Financial Condition · Key Business and Financial Metrics, page 66
SEC asked (5)
We note your disclosure that Net Revenue Retention Rate captures customer renewals, expansion, contraction, and churn. Please tell us if any of those underlying metrics are key metrics relied upon by management to evaluate the business. If so, provide a discussion of each metric and include quantified disclosure for each metric for each period presented.
DOCS answered

See the reply above.

Results of Operations, page 70
SEC asked (6)
For all periods presented, please revise to separately quantify and further analyze each significant factor contributing to the change for each of the line items discussed within the results of operations section.
Rest of the question

In regard to revenues, for example, please separately identify the amount of revenues generated from Marketing, Hiring, and Telehealth solutions and discuss the factors that drove growth and provide corresponding quantification of each factor or offset. When discussing associated costs, for instance, please identify and quantify headcount growth for your customer success teams. Refer to Item 303(a)(3)(iii) of Regulation S-K.

DOCS answered

See the reply above.

Non-GAAP Financial Measures, page 78
SEC asked (7)
Please accompany your presentations of Adjusted EBITDA margin with an equally prominent presentation of a comparable ratio calculated using GAAP amounts. Refer to Item 10(e)1(i)(A) of Regulation S-K and footnote 27 of non-GAAP adopting Release No. 33-8176.
DOCS answered

See the reply above.

Business, page 88
SEC asked (8)
Please revise to provide a discussion regarding the competing interests and priorities of your customers as compared to your members or users. In that regard, we note that you derive a majority of revenue from customers that target your users which may present a conflict for the company when the interests of your customers do not align with the interests of your members.
Rest of the question

As part of your discussion, address how the company will manage such conflicts.

DOCS answered

See the reply above.

Business, page 88
SEC asked (9)
You disclose that your platform provides members with a feed of relevant articles related to their field of practice. Please tell us whether you have any material agreements with third-party content providers, such as PubMed, and the terms of those agreements.
Rest of the question

In addition, please provide additional disclosure regarding whether access to third-party content providers are free for your users or if each user has to pay for access separately.

DOCS answered

See the reply above.

Business, page 88
SEC asked (10)
We note your disclosure that your Residency Navigator product "provides a transparent look into U.S. medical residency programs" to allow medical students to compare different programs. Please revise to clarify whether hospitals or residency programs can pay to improve their standing or to be seen by more medical students.
Rest of the question

In addition, please tell us whether you have any material agreements with any schools or residency programs to highlight those programs. 2. Summary of Significant Accounting Policies

DOCS answered

See the reply above.

Revenue Recognition, page F-11
SEC asked (11)
In order to better understand the nature of the services transferred in your arrangements, please clearly identify the nature of performance obligations specified in your contracts for each service line (Marketing, Hiring and Telehealth). For example, in regard to Marketing solutions, describe in further detail your typical contractual service obligations, including hosting sponsored content and messaging.
Rest of the question

Also clarify and explain the contractual provisions in your Marketing solution arrangements that result in multiple performance obligations, as compared to stand-ready obligations that are treated as a single performance obligation.

DOCS answered

See the reply above.

Revenue Recognition, page F-11
SEC asked (12)
For your arrangements that provide a series of stand-ready performance obligations, please tell us how you determined that this is a stand-ready obligation and recognizing revenue ratably over the term accurately depicts your performance in transferring control of the services promised to your customer. Refer to ASC 606-10-25-31.
DOCS answered

See the reply above.

Revenue Recognition, page F-11
SEC asked (13)
Your disclosure indicates that you recognize sales generated through the use of third-party media agencies on a gross basis since the Company is the principal in these transactions. Please describe the services provided by each party involved in these thirdparty transactions and tell us how you determined you control each service before it is transferred to the customer. Reference ASC 606-10-55-36 through 40.
DOCS answered

See the reply above.

Revenue Recognition, page F-11
SEC asked (14)
We note that you consider the services provided in Marketing solution subscriptions to be distinct and separate performance obligations "that represent a promise to provide a defined quantity of unique periods of services." Therefore, you allocate revenue to each individual period and recognize revenue as the control is transferred, which suggests point-in-time recognition when the services are delivered.
Rest of the question

Please clarify how this method of recognition "generally equates to ratably over the service period." In addition, please provide disclosures of revenues recognized at a point in time and over time for each service line disclosed in your footnote. We refer you to ASC 606-10-5091(f).

DOCS answered

See the reply above.

Revenue Disaggregation, page F-12
SEC asked (15)
We refer to your tabular disclosure of revenue by contract type. Please consider including disaggregated revenue by type of service since you disclose throughout the prospectus that you principally monetize your platform through your "Marketing, Hiring, and Telehealth Solutions." Reference is made to ASC 606-10-50-5 and ASC 606-10-55-91(a). Please revise or advise.
DOCS answered

See the reply above.

Deferred Revenue, page F-13
SEC asked (16)
Please clarify how the relationship between the timing of payment from your customer and the satisfaction of your performance obligation impacts your deferred revenue balances and when you expect to recognize as revenue the amount recognized as deferred revenue. Please refer to ASC 606-10-50-9 and 13. Your presentation should also include a roll-forward of your deferred revenue liability account, if material.
DOCS answered

See the reply above.

Note 6. Business Combinations, Intangible Assets, and Goodwill, page F-25
SEC asked (17)
Regarding your acquisition of Curative Talent, LLC, please explain to us your consideration of Rule 3-05 and Article 11 of Regulation S-X.
DOCS answered

See the reply above.

Note 10. Stock Option Plan, page F-30
SEC asked (18)
We note that that the fair value of your common stock is a key input to the determination of the fair value of your stock options. Please disclose the fair value of your common stock used in the determination of the fair value of your stock options for the period(s) presented.
DOCS answered

See the reply above.

Note 10. Stock Option Plan, page F-30
SEC asked (19)
Please provide us with a breakdown of all stock-based compensation awards granted since December 31 2020 including the fair value of the underlying stock used to value such awards. To the extent there was any significant fluctuations in the fair values, please describe for us the factors that contributed to such fluctuations, including any intervening events within the company or changes in your valuation
Rest of the question

assumptions or methodology. General

DOCS answered

See the reply above.

Note 10. Stock Option Plan, page F-30
SEC asked (20)
Please provide us with copies of all written communications, as defined in Securities Act Rule 405, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Securities Act Section 5(d), whether or not they retain copies of the communications.
DOCS answered

See the reply above.

SEC letter of Apr 30, 2021 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Results of Operations, page 70
SEC asked (1)
We note your response to prior comment 6. With respect to revenues, please consider revising to discuss further the underlying factors that resulted in an increase in subscription revenues from existing customers.
Rest of the question

For instance, since modules are the core building blocks of your customers’ marketing plan, please discuss and quantify increases in the number and types of modules sold in your Awareness, Interactivity, and Peer categories.

DOCS answered

No reply letter found.

Note 2. Summary of Significant Accounting Policies · Revenue Recognition, page F-11
SEC asked (2)
We note your response to prior comment 11. We also note you determined that integrated subscriptions are a stand-ready obligation, though your arrangements specifically limit the number of modules available and members targeted at any one time.
Rest of the question

Furthermore, your example explains that customers may utilize a defined number modules "with up to 20,000 targeted Doximity members at any given time during the subscription period." Please clarify how a customer's targeting of Doximity members up to contractual limits does not represent a discrete delivery of underlying services, particularly when you limit the customer's ability to use one or more modules at a time and your process of targeting members appears to diminish the targeted quantity available to the customer. In other words, please explain to us in greater detail the performance obligations that indicate your integrated subscriptions represent a promise to stand-ready for a period of time rather than to provide the underlying services, because it appears that you promise to provide a specified number of services during the contract term.

DOCS answered

No reply letter found.

Note 2. Summary of Significant Accounting Policies · Revenue Recognition, page F-11
SEC asked (3)
We note your response to prior comment 12. We also note in comment 11 you determined that "an output method of time" was the appropriate measure of progress when recognizing revenue for your integrated subscriptions. However, you state that there is uncertainty when, how often, and what modules the customer will want to present sponsored content to a target audience over the contract period.
Rest of the question

Accordingly, the pattern of benefit of these services, as well as your effort to fulfill the performance obligation, generally does not appear to be even throughout the contract period. Please tell us and clarify why the output method of elapsed time (i.e. straight-line) rather than upon service delivery best depicts the transfer of control of services to the customer. See ASC 606-1055-17.

DOCS answered

No reply letter found.

Letters without questions

Other letters

UPLOAD and CORRESP
2 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 8 letters filed since 2021-04-01. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/DOCS/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.